Plasmaflo OP-05W(A)
Asahi Kasei Medical Co., Ltd. · Decision date Sep 30, 2025
What did the FDA approve?
FDA records P820033/S017 as a supplement to PMA P820033, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Sep 30, 2025.
FDA approval order statement
Your supplement requested approval for a change in the supplier of the lubricant, calcium stearate, added to the polyethylene resin used in the manufacture of the hollow fiber of the device.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Sep 30, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P820033/S017
- Regulatory pathway
- PMA supplement
- Applicant
- Asahi Kasei Medical Co., Ltd.
- Product code
- MDP
- Decision code
- APPR
- Decision date
- Sep 30, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Separator for therapeutic purposes, membrane automated blood cell/plasma.
- Applicant
- Asahi Kasei Medical Co., Ltd.
- Product code
- MDP
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P820033/S017 received
Application receipt date recorded by FDA.
P820033/S017 · FDA decision
Real-Time Process
P820033/S019 · Related supplement
Plasmaflo OP-05 W(A)
Timeline entries are records held by MedtechLedger for P820033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P820033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Plasmaflo OP-05 W(A)P820033/S019 | Asahi Kasei Medical Co., Ltd. | PMA supplement | Apr 9, 2026 | FDA |
Explore the linked device profile
Other records with product code MDP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PRISMAFLEX TPE2000 SETP830063/S032 | Vantive US Healthcare, LLC | PMA supplement | Jul 15, 2026 | FDA |
Prismaflex TPE2000 SetP830063/S030 | Vantive US Healthcare, LLC | PMA supplement | Mar 13, 2026 | FDA |
Gambro Prismaflex TPE 2000 SetP830063/S031 | Vantive US Healthcare, LLC | PMA supplement | Dec 23, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Asahi Kasei Medical Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1-105 Kanda Jinbocho, Chiyoda-Ku, Tokyo, 101-8101
Sources and methodology
- Original FDA record: P820033/S017
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

